Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Jan;21(1):33–38. doi: 10.1128/aac.21.1.33

In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

E De Clercq, J Descamps, M Ogata, S Shigeta
PMCID: PMC181824  PMID: 6282207

Abstract

The in vitro susceptibility of eight strains of varicella-zoster virus (VZV) to E-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was examined in human embryonic fibroblasts by the following techniques: inhibition of focus formation by either cell-free VZV (4-day assay) or cell-associated VZV (2-day assay), inhibition of viral antigen formation (2-day assay), and inhibition of viral cytopathogenicity (15-day assay). The 50% inhibitory dose (ID50) of BVDU ranged from 0.001 microgram/ml (2-day assay) to 0.01 microgram/ml (15-day assay). BVDU appeared highly selective in its anti-VZV activity since even at concentrations as high as 100 micrograms/ml, BVDU did not markedly affect the viability of the host cells. The ID50 of BVDU for VZV was comparable to that of IVDU (E-5-(2-iodovinyl)-2'-deoxyuridine). Both drugs inhibited the replication of VZV at a much lower concentration than did other antiviral compounds such as iododeoxyuridine, ethyldeoxyuridine, arabinosylcytosine, arabinosyladenine, phosphonoacetic acid, iododeoxycytidine, and acycloguanosine. BVDU and IVDU were virtually inactive against a thymidine kinase-deficient VZV mutant, suggesting that phosphorylation by the viral enzyme is responsible, at least in part, for the selective anti-VZV activity of the compounds.

Full text

PDF
36

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allaudeen H. S., Kozarich J. W., Bertino J. R., De Clercq E. On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine. Proc Natl Acad Sci U S A. 1981 May;78(5):2698–2702. doi: 10.1073/pnas.78.5.2698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Biron K. K., Elion G. B. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother. 1980 Sep;18(3):443–447. doi: 10.1128/aac.18.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bryson Y. J., Connor J. D. In vitro susceptibility of varicella zoster virus to adenine arabinoside and hypoxanthine arabinoside. Antimicrob Agents Chemother. 1976 Mar;9(3):540–543. doi: 10.1128/aac.9.3.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cheng Y. C. A rational approach to the development of antiviral chemotherapy: alternative substrates of herpes simplex virus Type 1 (HSV-1) and Type 2 (HSV-2) thymidine kinase (TK). Ann N Y Acad Sci. 1977 Mar 4;284:594–598. doi: 10.1111/j.1749-6632.1977.tb21992.x. [DOI] [PubMed] [Google Scholar]
  5. Cheng Y. C., Dutschman G., De Clercq E., Jones A. S., Rahim S. G., Verhelst G., Walker R. T. Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins. Mol Pharmacol. 1981 Jul;20(1):230–233. [PubMed] [Google Scholar]
  6. Cheng Y. C., Tsou T. Y., Hackstadt T., Mallavia L. P. Induction of thymidine kinase and DNase in varicella-zoster virus-infected cells and kinetic properties of the virus-induced thymidine kinase. J Virol. 1979 Jul;31(1):172–177. doi: 10.1128/jvi.31.1.172-177.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Crumpacker C. S., Schnipper L. E., Zaia J. A., Levin M. J. Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother. 1979 May;15(5):642–645. doi: 10.1128/aac.15.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. De Clercq E., Descamps J., De Somer P., Barr P. J., Jones A. S., Walker R. T. (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2947–2951. doi: 10.1073/pnas.76.6.2947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. De Clercq E., Descamps J., Shugar D. 5-Propyl-2'-deoxyuridine: a specific anti-herpes agent. Antimicrob Agents Chemother. 1978 Mar;13(3):545–547. doi: 10.1128/aac.13.3.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  11. Dobersen M. J., Jerkofsky M., Greer S. Enzymatic basis for the selective inhibition of varicella-zoster virus by 5-halogenated analogues of deoxycytidine. J Virol. 1976 Nov;20(2):478–486. doi: 10.1128/jvi.20.2.478-486.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hackstadt T., Mallavia L. P. Deoxypyrimidine nucleoside metabolism in varicella-zoster virus-infected cells. J Virol. 1978 Feb;25(2):510–517. doi: 10.1128/jvi.25.2.510-517.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Iltis J. P., Lin T. S., Prusoff W. H., Rapp F. Effect of 5-iodo-5'-amino-2',5'-dideoxyuridine on varicella-zoster virus in vitro. Antimicrob Agents Chemother. 1979 Jul;16(1):92–97. doi: 10.1128/aac.16.1.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Johnson M. T., Buchanan R. A., Luby J. P., Mikulec D. Treatment of varicella-zoster virus infections with adenine arabinoside. J Infect Dis. 1975 Mar;131(3):225–229. doi: 10.1093/infdis/131.3.225. [DOI] [PubMed] [Google Scholar]
  15. Lopez C., Watanabe K. A., Fox J. J. 2'-fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent. Antimicrob Agents Chemother. 1980 May;17(5):803–806. doi: 10.1128/aac.17.5.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Machida H., Sakata S., Kuninaka A., Yoshino H. Antiherpesviral and anticellular effects of 1-beta-D-arabinofuranosyl-E-5-(2-halogenovinyl) uracils. Antimicrob Agents Chemother. 1981 Jul;20(1):47–52. doi: 10.1128/aac.20.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Miller R. L., Iltis J. P., Rapp F. Differential effect of arabinofuranosylthymine of the replication of human herpesviruses. J Virol. 1977 Sep;23(3):679–684. doi: 10.1128/jvi.23.3.679-684.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ogino T., Otsuka T., Takahashi M. Induction of deoxypyrimidine kinase activity in human embryonic lung cells infected with varicella-zoster virus. J Virol. 1977 Mar;21(3):1232–1235. doi: 10.1128/jvi.21.3.1232-1235.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. RAPP F., VANDERSLICE D. SPREAD OF ZOSTER VIRUS IN HUMAN EMBRYONIC LUNG CELLS AND THE INHIBITORY EFFECT OF LODODEOXYURIDINE. Virology. 1964 Mar;22:321–330. doi: 10.1016/0042-6822(64)90023-6. [DOI] [PubMed] [Google Scholar]
  20. Schmidt N. J., Lennette E. H. Improved yields of cell-free varicella-zoster virus. Infect Immun. 1976 Sep;14(3):709–715. doi: 10.1128/iai.14.3.709-715.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Selby P. J., Powles R. L., Janeson B., Kay H. E., Watson J. G., Thornton R., Morgenstern G., Clink H. M., McElwain T. J., Prentice H. G. Parenteral acyclovir therapy for herpesvirus infections in man. Lancet. 1979 Dec 15;2(8155):1267–1270. doi: 10.1016/s0140-6736(79)92281-5. [DOI] [PubMed] [Google Scholar]
  22. Torrence P. F., Spencer J. W., Bobst A. M. 5-O-Alkylated derivatives of 5-hydroxy-2'-deoxyuridine as potential antiviral agents. Anti-herpes activity of 5-propynyloxy-2'-deoxyuridine. J Med Chem. 1978 Feb;21(2):228–231. doi: 10.1021/jm00200a018. [DOI] [PubMed] [Google Scholar]
  23. Walz-Cicconi M. A., Martindale K. L., Weller T. H. Phosphonoacetic acid induced persistence of varicella-zoster virus in cell culture. Proc Soc Exp Biol Med. 1980 Jan;163(1):30–35. doi: 10.3181/00379727-163-40717. [DOI] [PubMed] [Google Scholar]
  24. Whitley R. J., Ch'ien L. T., Dolin R., Galasso G. J., Alford C. A., Jr Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N Engl J Med. 1976 May 27;294(22):1193–1199. doi: 10.1056/NEJM197605272942201. [DOI] [PubMed] [Google Scholar]
  25. de Clercq E., Degreef H., Wildiers J., de Jonge G., Drochmans A., Descamps J., de Somer P. Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster. Br Med J. 1980 Nov 1;281(6249):1178–1178. doi: 10.1136/bmj.281.6249.1178. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES